Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Zhejiang Genfleet Therapeutics Co. Ltd. manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. Prosecution is handled by 4 distinct examiners across 4 distinct art units. This indicates that each pending case is assigned to a unique examiner and unit, which prevents the concentration of the company's pending workload under any single individual. The presence of 4 distinct art units indicates that the company's current patent applications cover a variety of technical sub-sectors within the biotechnology field.
KWON, YONG SOK is the busiest examiner for the portfolio. This examiner is currently managing 1 pending office action for the company, indicating that the pending workload is divided equally among several examiners. Because the 4 pending office actions are spread across 4 distinct examiners, the applicant must navigate four different examination styles and unit-specific requirements. This decentralized approach to prosecution can lead to varying timelines for the resolution of each matter, as each of the 4 distinct art units may have different average response times and examination trends.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18723594 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KWON, YONG SOK | — |
| 18558139 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHTERENGARTS, SAMANTHA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | COLEMAN, BRENDA LIBBY | 50d overdue |
| 18282254 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HEASLEY, MEGHAN CHRISTINE | 56d |
| 18723594 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1623 | 1 |
| 1624 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723594 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KWON, YONG SOK | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18558139 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §102§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §112Other | Final Rejection | 50d overdue | Pending | Oct 17, 2023 |
| 18282254 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §102 | Non-Final OA | 56d | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Genfleet Therapeutics Co. Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Yong Sok Kwon has the most, with 1 of Zhejiang Genfleet Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
